OmniAb Lifts 2026 Revenue and Cash Guidance After Q3 Revenue Nearly Doubles
OABI has more than doubled off its 52-week low of $1.3.
Summary
OmniAb raised full-year 2026 revenue guidance to $35-39 million from $32-36 million and lifted its year-end cash outlook to $53-57 million from $49-53 million, while cutting its 2026 cost outlook to $83-87 million from $84-88 million and cash costs to $50-54 million from $51-55 million. Q3 revenue came in at $4.0 million versus $2.2 million a year earlier, driven by service work on antibody and ion channel programs plus higher xPloration instrument and consumable sales. The quarter still carried a $15.7 million net loss, or $0.12 per share, though that narrowed from $16.5 million a year ago, and the company held $64.2 million in cash, equivalents and short-term investments at September 30. The bigger swing this year came earlier: nine-month revenue reached $31.8 million versus $10.3 million, mostly from milestone revenue, following the August Eli Lilly ion channel collaboration worth up to $370 million in milestones. Management also flagged the broad commercial launch of xPloration in October, targeting a market it pegs at more than $500 million, with xPloration revenue expected at $2-3 million in 2026 and doubling in each of 2027 and 2028. The 8:00 a.m. ET call today is where guidance credibility and the xPloration ramp get tested.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — OmniAb cut its 2026 cost outlook to $83-87 million from $84-88 million and cash costs to $50-54 million from $51-55 million.
At the time of this announcement, OABI was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.4M. The 52-week trading range was $1.30 to $5.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.